Novel Clinical Trial Designs In Oncology: An Histology-Independent Approach
Executive Summary
Cancer’s heterogeneity is a leading reason why product development in this therapeutic area is so risky and costly – and why the pharma industry has not yet addressed all needs in the market. Because low-incidence tumors present recruitment challenges and have lower commercial potential than high-incidence ones, they receive less attention from drug developers; meanwhile, new therapies for high-incidence tumors must demonstrate higher efficacy than therapeutic alternatives in order to differentiate themselves.
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.